ストックスクリーナーアプリを入手
10.97
0.46%
0.05
プレマーケット:
11.10
0.13
+1.19%
Immix Biopharma Inc (IMMX) 最新ニュース
Immix Biopharma Stock Price Forecast. Should You Buy IMMX? - StockInvest.us
Immix Biopharma (NASDAQ:IMMX) Stock Price Down 4.5%Here's Why - MarketBeat
Immix Biopharma (IMMX) gains 5.6% stake holder led by Eventide Asset Management - Stock Titan
Citizens reiterates Immix Biopharma stock rating on pipeline progress - Investing.com
Citizens reiterates Immix Biopharma stock rating on pipeline progress By Investing.com - Investing.com India
Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating - Moomoo
Janus Henderson Group (IMMX) discloses 9.78M-share beneficial stake in Immix Biopharma - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc.IMMX - PR Newswire
Immix Biopharma Q3 EPS Estimate Lowered by HC Wainwright - MarketBeat
Immix Biopharma (NASDAQ:IMMX) Trading 7.1% HigherStill a Buy? - MarketBeat
HC Wainwright Estimates Immix Biopharma FY2027 Earnings - MarketBeat
Immix Biopharma publishes corporate presentation on NXC-201 BCMA CAR-T in relapsed/refractory AL amyloidosis - Bitget
Immix Biopharma, Inc. Stock 12‑Month Price Target Cut to $20.44, Implies 102% Upside - TradingView
Immix Biopharma (IMMX) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
IMMIX BIOPHARMA, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $25 FROM $20 - Bitget
H.C. Wainwright raises Immix Biopharma price target to $25 By Investing.com - Investing.com Australia
H.C. Wainwright raises Immix Biopharma price target to $25 - Investing.com India
Regulatory and Data Risks Loom Over Immix Biopharma’s Clinical Programs and Valuation - TipRanks
Immix Biopharma (NASDAQ:IMMX) Announces Quarterly Earnings Results - MarketBeat
Immix Biopharma (NASDAQ: IMMX) ends Q2 2026 with $232.1M in cash - Stock Titan
Immix Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Immix Biopharma (NASDAQ:IMMX) Stock Price Down 6.7%Here's What Happened - MarketBeat
Immix Biopharma Inc (IMMX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immix Biopharma (IMMX) Projected to Post Quarterly Earnings on Friday - MarketBeat
IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law - Business Wire
Immix Biopharma, Inc. (NASDAQ:IMMX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Immix Biopharma faces investigation after hirin... - Pluang
Immix Biopharma, Inc. expected to post a loss of 18 cents a shareEarnings Preview - TradingView
Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - The Manila Times
Immix Biopharma Announces Participation in Morgan Stanley 24th Annual Global Healthcare Conference and Institutional Investor Meetings - Quiver Quantitative
Janus Henderson Group PLC Boosts Stake in Immix Biopharma, Inc. $IMMX - MarketBeat
IMMX INVESTIGATION: Immix Biopharma Investors Who Lost Money After Reports About Its Former CMO Should Contact Block & Leviton - ACCESS Newswire
Immix Biopharma Inc. (IMMX) Q1 2026 Earnings: EPS Beats Estimates on Lower Loss, Stock Gains 4.65%Subscription Growth Report - dars.gov.et
Immix Biopharma Inc (IMMX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IMMX|Immix Biopharma Inc|Price:8.690|Chg%:+0.170 - TradingKey
Immix Biopharma Inc (IMMX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immix Biopharma Inc (IMMX) Cash Flow - TradingKey
Immix Biopharma (NASDAQ:IMMX) Stock Price Up 9.7%What's Next? - MarketBeat
Immix Biopharma, Inc. Revenue Breakdown – NASDAQ:IMMX - TradingView
Immix Biopharma Inc (IMMX) Income Statement - TradingKey
Immix Biopharma Inc (IMMX) Balance Sheet - TradingKey
Immix Biopharma Inc (IMMX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immix Biopharma Inc (IMMX) Institutional Confidence - TradingKey
Immix Biopharma Inc (IMMX) Risk Assessment: Volatility, Financial Risk & Investment Risk - tradingkey.com
Immix Biopharma Inc (IMMX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immix Biopharma Inc (IMMX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IMMX|Immix Biopharma Inc|Price:9.070|Chg%:+0.550 - TradingKey
IMMX|Immix Biopharma Inc|Price:8.593|Chg%:-0.207 - TradingKey
EQPT LAWSUIT: EquipmentShare.com Inc. Sued for Securities Law Violations; Investors Should Contact Block & Leviton To Learn How They Might Recover Their Losses - GlobeNewswire Inc.
Immix Biopharma, Inc. (IMMX) options chain - Yahoo Finance Australia
Immix Biopharma, Inc. At-The-Market Equity Offering · $5M raised · (2023) - StartupHub.ai
symbol__ Stock Quote Price and Forecast - CNN
IMMX Initiated Coverage by Needham -- Rating Set to Buy - GuruFocus
Needham Initiates Immix Biopharma(IMMX.US) With Buy Rating, Announces Target Price $21 - Moomoo
Fugitive doctor on run for 21 years was living as L.A. biotech exec - KTLA
Immix Biopharma drops after chief medical officer terminated - MSN
Sex offender, a fugitive for 21 years, hid in plain sight as a yacht-owning L.A. biopharma exec - Los Angeles Times
Immix Biopharma Investigated by the Portnoy Law Firm - GlobeNewswire
Five things for pharma marketers to know for Tuesday, July 21, 2026 - Medical Marketing and Media
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):